A New Breast Cancer Arising Beneath an Accessory Nipple

This breast cancer diagnosis at a glance

Subtype
Invasive Lobular Carcinoma
Biomarkers
ER 5%; PR 5–10%; HER2-negative.
Sex
Female
Treatment
chemotherapy, surgery, hormone therapy, radiation and reconstruction
Outcome
Cancer-Free / NED

Treatment course, step by step

  1. Neoadjuvant cyclophosphamide and docetaxel chemotherapy was given.
  2. Wide local excision was performed with removal of the accessory nipple.
  3. Postoperative capecitabine chemotherapy was given.
  4. Endocrine therapy followed.
  5. Proton therapy delivered 2 cobalt Gray-equivalents for 25 fractions to the chest wall and regional nodes.
  6. A tumor-bed boost delivered 2 cobalt Gray-equivalents for 8 fractions.
  7. Reconstruction was revised two years later with a DIEP flap.

What happened, in summary

A 44-year-old woman noticed a mass at the inframammary fold beneath a supernumerary nipple five years after treatment for a separate left-breast invasive ductal carcinoma. Ultrasound showed an irregular lesion, and biopsy identified poorly differentiated invasive lobular carcinoma. The new tumor expressed estrogen receptor at 5% and progesterone receptor at 5%, while HER2 was negative. PET imaging found no distant metastasis. MRI showed a 2.5 cm mass extending into the left rectus abdominis muscle.

She received neoadjuvant cyclophosphamide and docetaxel, with a favorable response on repeat imaging. A wide local excision removed the cancer together with the accessory nipple. Final pathology showed 3.3 cm of residual invasive lobular carcinoma with negative margins. The residual tumor remained weakly hormone-receptor positive, with ER at 5% and PR at 5% to 10%, and HER2-negative.

Postoperative treatment included capecitabine followed by endocrine therapy. Proton radiation was delivered to the chest wall and regional lymph nodes in 25 fractions, followed by an eight-fraction boost to the tumor bed along the inframammary fold. Two years later, she underwent revision of her breast reconstruction with a DIEP flap. She was described as currently having no evidence of disease. The different histology, receptor profile, and five-year interval supported classification as a new primary cancer in accessory breast tissue rather than recurrence of her earlier triple-negative tumor.

Where this story comes from

This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full

How we source and attribute stories Accuracy and limitations

Collections this story belongs to

Similar breast cancer stories

These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer

Search more breast cancer stories